THE ANALYSIS OF INFLUENCE OF CLINICAL PREDICTORS ON THE RESULTS OF TREATMENT WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Salajka, Frantisek [1 ]
Pesek, Milos [2 ]
Krejci, Jana [3 ]
Skrickova, Jana [4 ]
Zatloukal, Petr
Koubkova, Leona
Grygarkova, Ivona
Hrnciarik, Michal [1 ]
Sticha, Michal [5 ]
机构：
[1] Univ Hosp, Dept Pneumol, Bulovka, Czech Republic
[2] Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[3] Charles Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[4] Univ Hosp Brno, Dept Resp Dis & Tb, Brno, Czech Republic
[5] Masaryk Univ, CS-60177 Brno, Czech Republic
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; erlotinib; clinical predictors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1293 / S1294
页数：2
相关论文
共 50 条
  • [31] ERLOTINIB IN THE TREATMENT OF NON-SMALL CELL LUNG CARCINOMA (NSCLC) - A CZECH RETROSPECTIVE ANALYSIS
    Pesek, M.
    Zatloukai, P.
    Skrickova, J.
    Kolek, V.
    Koubkova, L.
    Salajka, F.
    Sixtova, D.
    Zemanova, M.
    Roubec, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 122 - 122
  • [32] ERLOTINIB FOR CHINESE ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Wang, H-P
    Li, Z.
    Wang, M-Z
    Yi, X.
    RESPIROLOGY, 2011, 16 : 172 - 172
  • [33] Erlotinib (Tarceva) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1205): : 25 - 26
  • [34] Neoadjuvant treatment in the clinical practice of locally advanced non-small cell lung cancer (NSCLC).
    Arcuri, C
    Caffo, O
    Vanoni, V
    Silvestri, M
    Valduga, F
    Santarossa, S
    Galligioni, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [35] Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment
    Wang Yong-sheng
    Miao Li-yun
    Liu Lu
    Cai Hou-rong
    Ding Jing-jing
    Ren Sheng-xiang
    Zhou Cai-cun
    Schmid-Bindert, Gerald
    CHINESE MEDICAL JOURNAL, 2013, 126 (20) : 3931 - 3935
  • [36] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    M. Faehling
    J. Achenbach
    P. Staib
    U. Steffen
    H. W. Tessen
    V. E. Gaillard
    W. Brugger
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1375 - 1383
  • [37] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Brugger, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Gaillard, V. E.
    Brugger, W.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1375 - 1383
  • [39] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [40] Cost effectiveness of erlotinib in the treatment of advanced non small cell lung cancer (NSCLC) in Poland
    Orlewska, E.
    Szczesna, A.
    Gyldmark, M.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2006, 9 (06) : A279 - A279
12345